Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.

Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.

A key challenge in the development of precision medicine is defining the phenotypic consequences of pharmacological modulation of specific target macromolecules. To address this issue, a variety of genetic, molecular and chemical tools can be used. All of these approaches can produce misleading resu...

Full description

Bibliographic Details
Main Authors: Michael J Thomenius, Jennifer Totman, Darren Harvey, Lorna H Mitchell, Thomas V Riera, Kat Cosmopoulos, Alexandra R Grassian, Christine Klaus, Megan Foley, Elizabeth A Admirand, Haris Jahic, Christina Majer, Tim Wigle, Suzanne L Jacques, Jodi Gureasko, Dorothy Brach, Trupti Lingaraj, Kip West, Sherri Smith, Nathalie Rioux, Nigel J Waters, Cuyue Tang, Alejandra Raimondi, Michael Munchhof, James E Mills, Scott Ribich, Margaret Porter Scott, Kevin W Kuntz, William P Janzen, Mikel Moyer, Jesse J Smith, Richard Chesworth, Robert A Copeland, P Ann Boriack-Sjodin
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5983452?pdf=render

Internet

http://europepmc.org/articles/PMC5983452?pdf=render

Similar Items